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A feasibility study of accelerated polychemotherapy with cisplatin,
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Summary We have evaluated the feasibility of an increase in dose intensity of the cisplatin, epidoxorubicin
and cyclophosphamide (PEC) regimen, with granulocyte colony-stimulating factor (G-CSF) support, in 22
patients with advanced ovarian cancer. Twenty-one patients (95.4%) received six cycles of treatment: of these,
13 (61.9%) were also able to repeat cycles every 14 days as planned. Marrow toxicity was similar to that
observed during conventional treatments. No severe mucositis or thrombocytopenia was observed. A clinical
complete response was observed in 9 out of 16 evaluable patients (56.2%).
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The importance of dose intensity in chemotherapy, i.e. the
amount of drug delivered per unit of time, has been stressed
in several experimental and clinical contributions after early
retrospective analyses by Hryniuk and Bush (1984) and
Hryniuk (1987) underlined the relationship between planned
dose intensity and response rate in breast cancer. Based on
another retrospective study (Levine and Hryniuk, 1987),
ovarian cancer appears to be a particularly suitable model for
intensification of chemotherapy: however, prospective data
about the use of intensified regimens in this disease are still
scarce.
In the present study we have evaluated the feasibility of an
increase of the dose intensity of a polychemotherapy regimen
commonly used in ovarian cancer (PEC; cisplatin, epidoxor-
ubicin and cyclophosphamide) (Conte et al., 1993). Such
increase was obtained reducing the intervals between cycles,
with the use of granulocyte colony-stimulating factor
(filgrastim, G-CSF) as prophylactic supportive treatment.
Patients and methods
To be eligible for the trial, patients had to have histological
diagnosis of epithelial ovarian carcinoma; previous adequate
cytoreductive surgery was required, with FIGO III -IV
staging; serum creatinine, serum bilirubin and haemogram
had to be within normal limits. Informed consent was
obtained from all patients.
Chemotherapy consisted of cisplatin 50 mg m-2, epidox-
orubicin 60 mg m-2 and cyclophosphamide 600 mg m-2, all
administered intravenously on day 1 every 14 days for six
cycles. Filgrastim was administered subcutaneously from day
4 to day 9 between cycles.
In the case of incomplete marrow recovery (WBC
< 3000 mm-' and/or platelets < 100.000 mm-3) on day 1
of the cycle, chemotherapy was delayed for 1 week or until
complete marrow recovery. In the case of haemoglobin levels
of 9 g dl-' or less a blood transfusion was supplied and
chemotherapy was not postponed. In the case of a platelet
count of 50 000 mm-3 or less, detected at any time during
therapy, a 50% reduction of the doses of all drugs was
planned for the remaining courses.
The primary aim of the study was to evaluate the feasibility
of accelerated PEC treatment: the activity of the treatment
was also assessed according to WHO response criteria.
Toxicity was evaluated according to ECOG criteria.
Planned and total delivered dose intensity were calculated
as the amount of drug (mg m-2) administered per unit of
time (week), according to the indications of Hryniuk and
Bush (1984) and Coppin (1987). The planned dose intensity
was 25 mg m-2 per week for cisplatin, 30 mg m-2 per week
for epidoxorubicin and 300 mg m-2 per week for cyclopho-
sphamide. For each patient, the actually delivered dose
intensity (received dose intensity, RDI) was calculated as a
percentage of the planned one
Results
Twenty-two patients entered the trial. The main character-
istics of patients are shown in Table I. One patient refused to
continue the trial after two cycles. Twenty-one patients
(95.4%) received all six cycles of PEC without any reduction
in doses: of these, 13 (59.1%) also completed the treatment
without delays between cycles. Two patients (9.5%)
completed the treatment with a delay of 1 week (between
the fifth and the sixth cycle), and four (19%) with a delay of
2 weeks (1 week between the fourth and the fifth cycle and 1
week between the fifth and the sixth cycle). A delay greater
than 2 weeks (respectively of 4 and 5 weeks) occurred in two
patients (9.5%), one of which was suffering grade III acute
emesis and delayed emesis that caused a poor compliance to
chemotherapy, while the second patient delayed the cycles
because of psychological distress.
The average RDI in the 21 evaluable patients was 93.9%
of the planned one (range 70.3% -100%): in 19 cases (90.5%;
95% confidence limits, 77.9% - 100%) RDI was at least 85%
of planned, and in 13 cases (61.9%; 95% confidence limits,
41.1%-82.7%) it was 100% of the planned intensity.
A clinical complete response, as confirmed by compu-
terised tomography (CT) scan, serum markers and pelvic
examination, was observed in nine patients (56.2%) out of
the 16 who entered the trial having evaluable disease after
surgery.
Toxicities are shown in Table II. Values of WBC, platelets
and haemoglobin during treatment are shown in Table III.
An overall decline of platelets and leucocytes was observed.
This decline reached levels lower than those required for
recycle in eight cases (in the last two cycles). In spite of the
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Table I Characteristics of patients (n=22)
Median age, years (range)
FIGO stage, no. of patients (%)
IIIA
IIIB
IIIC
IV
Histology, no. of patients (%)
Serous carcinoma
Mucinous carcinoma
Malignant endometrioid tumour
Clear cell tumour
Performance status, no. of patients (%)
0
1
51 (39-70)
5 (22.7)
7 (31.8)
8 (36.4)
2 (9.1)
12 (54.0)
5 (22.7)
3 (13.6)
2 (9.1)
12 (54.5)
10 (45.4)
Table II Toxicity - worst ever toxicity experienced by patients, no.
of patients (%)
ECOG scale
0 1 2 3 4
Nausea 2(9.1) 14(63.6) 4(18.2) 2(9.1) -
and vomit-
ing
Stomatitis 19(86.4) 2(9.1) 1(4.5)
Neuropa- 21(95.4) 1(4.5)
thy
Hair loss - 1(4.5) 2(9.1) 19(86.4)
Skeletal 3(13.6) 17(77.3) 2(9.1)
pain
Dizziness 21(95.4) 1(4.5)
Cardiac 21(95.4) 1(4.5)
Table III Median values (range) of haemoglobin (Hb, g dl-1), white blood cells (WBC, n mm-3) and platelets (PLT, n x 103 mm-3) on day
14 after each cycle of chemotherapy
Cycle number
1 2 3 4 5 6
Hb 12.1 11.8 11.4 10.5 10.4 9.5
(10.1 -13.1) (10.1-13.8) (9.5-12.5) (8.5- 12.8) (8.1 -12.0) (9.1 -11.2)
WBC 4950 4380 3710 3520 3320 3300
(3800-9100) (3380-5150) (33280-4100) (3150-4720) (2250-41500 (2100-4350)
PLT 319 235 189 175 154 162
(156-413) (132-310) (128-325) (120-285) (79-225) (85- 193)
general decline observed in blood cells, only six patients had
haemoglobin levels below 9 g dl-' and needed a red cell
transfusion. No case of febrile neutropenia was observed.
Discussion
Since the introduction of platinum-based combinations, the
prognosis of advanced ovarian carcinoma has improved
(Nejit et al., 1987; Gruppo Interregionale Cooperativo
Oncologia Ginecologica, 1987). To assess the possibility of
further progress, researchers in recent years have explored
fields such as the association of platinum and anthracyclines
(Ovarian Cancer Meta-analysis Project, 1991) and the issue of
dose intensity: retrospective analyses, in fact, showed a direct
relationship between clinical results and average relative dose
intensity, i.e. a mean of the dose intensities of each drug in
different regimens (Levine and Hryniuk, 1987). There are
basically two ways to increase the dose intensity of a
chemotherapy regimen: the first is to increase the dose of
drugs in each cycle, while the second is to shorten the
intervals between standard-dosed cycles. Based on the
characteristics of available growth factors (G-CSF and
GM-CSF), which allow a more rapid marrow recovery from
previous chemotherapy (Crawford et al., 1991; Gabrilove et
al., 1988; Bronchud et al., 1989), we have chosen in the
present study to accelerate a combination of cisplatin,
epidoxorubicin and cyclophosphamide (PEC) that is often
used in our country (Conte et al., 1993). Cycles were to be
repeated every 2 weeks instead of every 3 or 4 weeks as is
usual when PEC is administered without growth factor
support. The results show the feasibility of such an
accelerated regimen, with 90% of patients being able to
receive at least 85% of the planned dose intensity and more
than 60% receiving 100%. Since the addition of anthracy-
clines generally results in a reduction of dose intensity of
cyclophosphamide and cisplatin, our study suggests that G-
CSF support is not only able to avoid this, but is also able to
obtain a consistent increase of dose intensity in a very
manageable way. No life-threatening toxicity was observed
and marrow toxicity remained similar to that reported during
conventional treatments. Interestingly, in spite of the
increased dose intensity, no severe mucositis or thrombocy-
topenia were observed.
The issue of the possible clinical advantages associated
with an increase of dose intensity, however, cannot be
resolved by this study. Other trials have reported contrasting
data. One study (Bolis et al., 1994) compared weekly cisplatin
vs standard cisplatin plus cyclophosphamide given every 3
weeks: as the two regimens had superimposable results, at
least in patients with residual tumour >2 cm after surgery, it
was suggested that the intensification of cisplatin is able to
counterbalance the possible disadvantage of using single-
agent chemotherapy.
The Gynecology Oncology Study Group (1987) has
specifically tested the hypothesis of dose intensity in a
randomised study comparing two planned doses of cisplatin
and cyclophosphamide: in spite of the achievement of a
significantly higher actually delivered dose intensity, better
clinical results were not obtained with respect to conventional
doses (McGuire and Hoskins, 1992). More encouraging
results were reported by Kaye et al. (1992) in a comparative
trial of two different dose intensities of cisplatin and
cyclophosphamide, which was closed because of a significant
survival advantage for the higher doses; however, long-term
follow-up showed a reduced survival benefit (Kaye, 1995).
The Italian cooperative group GONO has compared two
regimens of PEC using cisplatin at the dose of 50 mg 2
and 100 mg-2 respectively (Conte et al., 1993). The high-dose
cisplatin regimen seemed significantly more toxic but not
more active, although definitive results are not available.
On the whole, the possibility of obtaining clinical benefits
from an increase of chemotherapy dose intensity in ovarian
cancer still seems controversial. Future studies should also
examine aspects such as quality of life and cost/benefit
considerations: other interesting data may derive from the
exploration of much higher dose intensity increases,
obtainable for example with peripheral blood stem cell
reinfusion.
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